<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04676815</url>
  </required_header>
  <id_info>
    <org_study_id>YHe</org_study_id>
    <nct_id>NCT04676815</nct_id>
  </id_info>
  <brief_title>Narrow Band Imaging (NBI) Under Electronic Bronchoscope in Lung Cancer</brief_title>
  <official_title>Application of Narrow Band Imaging (NBI) Under Electronic Bronchoscope in the Diagnosis and Staging of Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Pulmonary Hospital, Shanghai, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Pulmonary Hospital, Shanghai, China</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Narrow-Band Imaging (NBI) is useful to better demarcate the superficial extent of central&#xD;
      type of lung cancer, but its sensitivity and specificity in clinical practice were little&#xD;
      studied. This study aimed to investigate the diagnostic effects of NBI in suspected patients&#xD;
      with central lung cancer and its application in staging diagnosis of central lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      With high morbidity and mortality, lung cancer is one of the most common tumors in the world.&#xD;
      Therefore, early detection, accurate diagnosis and staging division can effectively guide&#xD;
      clinical interventions, thereby improving patient survival. Narrowband imaging under&#xD;
      electronic bronchoscope (NBI) is an emerging optical image emphasis technology that can&#xD;
      enhance the contrast between the mucosal surface and underlying blood vessels, specifically&#xD;
      display the distribution of blood vessels, and highlight the subtle changes in mucosal&#xD;
      structure. Meanwhile, it can reduce unnecessary biopsy with low risk and costs. In recent&#xD;
      years, NBI technology has gradually begun to show its unique advantages in the diagnosis of&#xD;
      gastric cancer, esophageal cancer, nasopharyngeal cancer, and bladder cancer. The purpose of&#xD;
      this study is to explore the diagnostic value of NBI under electronic bronchoscopy for early&#xD;
      detection and accurate diagnosis of lung cancer, and to provide a more economical, safer and&#xD;
      more efficient diagnosis option for lung cancer patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2021</start_date>
  <completion_date type="Anticipated">April 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The specificity of diagnosis of NBI plus electronic bronchoscopy in central type lung cancer</measure>
    <time_frame>4 months</time_frame>
    <description>Abnormal blood vessels or lack of staining is defined as suspected lesions. All the suspected lesions were biopsied.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The sensitivity, positive predictive value, and negative predictive value.</measure>
    <time_frame>4 months</time_frame>
    <description>Abnormal blood vessels or lack of staining is defined as suspected lesions. All the suspected lesions were biopsied.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Malignant Airway Obstruction</condition>
  <arm_group>
    <arm_group_label>NBI PATIENT</arm_group_label>
    <description>Diagnostic Test: NBI in combination with electronic bronchoscope</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-NBI PATIENT</arm_group_label>
    <description>Diagnostic Test: Electronic bronchoscope without NBI</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>NBI and interventional bronchoscopy</intervention_name>
    <description>NBI used to enhance the contrast between the mucosal surface and underlying blood vessels</description>
    <arm_group_label>NBI PATIENT</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        HIGH RISK OF CENTRAL TYPE OF LUNG CANCER&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Patients had a history or current central lung cancer&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - NONE&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yayi He, Ph.D, MD</last_name>
    <phone>+8621 65115006</phone>
    <email>2250601@qq.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Pulmonary Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yayi He, Ph.D</last_name>
      <phone>+8621 65115006</phone>
      <email>2250601@qq.com</email>
    </contact>
    <investigator>
      <last_name>Yayi He, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ye Gu, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Wen S, Dai L, Wang L, Wang W, Wu D, Wang K, He Z, Wang A, Chen H, Zhang P, Dong X, Dong YA, Wang K, Yao M, Wang M. Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer. Oncologist. 2019 Nov;24(11):e1070-e1081. doi: 10.1634/theoncologist.2018-0572. Epub 2019 Mar 22.</citation>
    <PMID>30902917</PMID>
  </results_reference>
  <results_reference>
    <citation>Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Akinyemiju TF, Al Lami FH, Alam T, Alizadeh-Navaei R, Allen C, Alsharif U, Alvis-Guzman N, Amini E, Anderson BO, Aremu O, Artaman A, Asgedom SW, Assadi R, Atey TM, Avila-Burgos L, Awasthi A, Ba Saleem HO, Barac A, Bennett JR, Bensenor IM, Bhakta N, Brenner H, Cahuana-Hurtado L, Castañeda-Orjuela CA, Catalá-López F, Choi JJ, Christopher DJ, Chung SC, Curado MP, Dandona L, Dandona R, das Neves J, Dey S, Dharmaratne SD, Doku DT, Driscoll TR, Dubey M, Ebrahimi H, Edessa D, El-Khatib Z, Endries AY, Fischer F, Force LM, Foreman KJ, Gebrehiwot SW, Gopalani SV, Grosso G, Gupta R, Gyawali B, Hamadeh RR, Hamidi S, Harvey J, Hassen HY, Hay RJ, Hay SI, Heibati B, Hiluf MK, Horita N, Hosgood HD, Ilesanmi OS, Innos K, Islami F, Jakovljevic MB, Johnson SC, Jonas JB, Kasaeian A, Kassa TD, Khader YS, Khan EA, Khan G, Khang YH, Khosravi MH, Khubchandani J, Kopec JA, Kumar GA, Kutz M, Lad DP, Lafranconi A, Lan Q, Legesse Y, Leigh J, Linn S, Lunevicius R, Majeed A, Malekzadeh R, Malta DC, Mantovani LG, McMahon BJ, Meier T, Melaku YA, Melku M, Memiah P, Mendoza W, Meretoja TJ, Mezgebe HB, Miller TR, Mohammed S, Mokdad AH, Moosazadeh M, Moraga P, Mousavi SM, Nangia V, Nguyen CT, Nong VM, Ogbo FA, Olagunju AT, Pa M, Park EK, Patel T, Pereira DM, Pishgar F, Postma MJ, Pourmalek F, Qorbani M, Rafay A, Rawaf S, Rawaf DL, Roshandel G, Safiri S, Salimzadeh H, Sanabria JR, Santric Milicevic MM, Sartorius B, Satpathy M, Sepanlou SG, Shackelford KA, Shaikh MA, Sharif-Alhoseini M, She J, Shin MJ, Shiue I, Shrime MG, Sinke AH, Sisay M, Sligar A, Sufiyan MB, Sykes BL, Tabarés-Seisdedos R, Tessema GA, Topor-Madry R, Tran TT, Tran BX, Ukwaja KN, Vlassov VV, Vollset SE, Weiderpass E, Williams HC, Yimer NB, Yonemoto N, Younis MZ, Murray CJL, Naghavi M. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 2018 Nov 1;4(11):1553-1568. doi: 10.1001/jamaoncol.2018.2706.</citation>
    <PMID>29860482</PMID>
  </results_reference>
  <results_reference>
    <citation>Subramanian V, Ragunath K. Advanced endoscopic imaging: a review of commercially available technologies. Clin Gastroenterol Hepatol. 2014 Mar;12(3):368-76.e1. doi: 10.1016/j.cgh.2013.06.015. Epub 2013 Jun 28. Review.</citation>
    <PMID>23811245</PMID>
  </results_reference>
  <results_reference>
    <citation>Ueda T, Dohi O, Naito Y, Yoshida T, Azuma Y, Ishida T, Matsumura S, Kitae H, Takayama S, Mizuno N, Nakano T, Iwai N, Hirose R, Inoue K, Yoshida N, Kamada K, Uchiyama K, Ishikawa T, Takagi T, Konishi H, Nishimura A, Kishimoto M, Itoh Y. Diagnostic performance of magnifying blue laser imaging versus magnifying narrow-band imaging for identifying the depth of invasion of superficial esophageal squamous cell carcinoma. Dis Esophagus. 2021 Mar 8;34(3). pii: doaa078. doi: 10.1093/dote/doaa078.</citation>
    <PMID>32691042</PMID>
  </results_reference>
  <results_reference>
    <citation>Ueyama H, Kato Y, Akazawa Y, Yatagai N, Komori H, Takeda T, Matsumoto K, Ueda K, Matsumoto K, Hojo M, Yao T, Nagahara A, Tada T. Application of artificial intelligence using a convolutional neural network for diagnosis of early gastric cancer based on magnifying endoscopy with narrow-band imaging. J Gastroenterol Hepatol. 2021 Feb;36(2):482-489. doi: 10.1111/jgh.15190. Epub 2020 Jul 28.</citation>
    <PMID>32681536</PMID>
  </results_reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 16, 2020</study_first_submitted>
  <study_first_submitted_qc>December 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 21, 2020</study_first_posted>
  <last_update_submitted>January 4, 2021</last_update_submitted>
  <last_update_submitted_qc>January 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Pulmonary Hospital, Shanghai, China</investigator_affiliation>
    <investigator_full_name>Yayi He</investigator_full_name>
    <investigator_title>Associate Chief Physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Airway Obstruction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

